Navigation Links
Shire Extends Tender Offer for ViroPharma
Date:1/10/2014

DUBLIN, January 10, 2014 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has extended the expiration of its previously announced tender offer by a wholly owned subsidiary of Shire for all of the outstanding common shares of ViroPharma Incorporated (NASDAQ: VPHM) until midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014).  The tender offer had previously been scheduled to expire at midnight, New York City time, on Thursday, January 9, 2014 (one minute after 11:59 p.m., New York City time, on January 9, 2014).  All of the other terms and conditions of the tender offer remain unchanged.

As of midnight on January 9, 2014, approximately 51,571,041 common shares of ViroPharma (excluding 2,120,493 common shares of ViroPharma guaranteed to be delivered within the next three NASDAQ trading days) had been validly tendered and not withdrawn pursuant to the tender offer, representing approximately 78 percent of the outstanding common shares of ViroPharma.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

http://www.shire.com

ADDITIONAL INFORMATION AND WHERE TO FIND IT  

This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell ViroPharma common stock. The offer to buy ViroPharma common stock is being made pursuant to a tender offer statement (including the offer to purchase, letter of transmittal and other related tender offer materials) filed by Shire Pharmaceutical Holdings Ireland Limited (SPHIL) and a subsidiary of SPHIL with the U.S. Securities and Exchange Commission (SEC) on November 25, 2013.  In addition, on November 25, 2013, ViroPharma filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer.  Investors and security holders are urged to read both the tender offer statement and the solicitation/recommendation statement as they contain important information, including the terms and conditions of the tender offer, that should be read carefully before any decision is made with respect to the tender offer.  Investors and security holders may obtain a free copy of these materials and other documents filed by SPHIL and ViroPharma with the SEC at the website maintained by the SEC at http://www.sec.gov/. The tender offer statement and related materials, and the solicitation/recommendation statement, may also be obtained for free by contacting the information agent for the offer, MacKenzie Partners, Inc., at (212) 929-5500 or toll-free at (800) 322-2885.

Copies of these materials and any documentation relating to the tender offer are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from any jurisdiction where to do so would be unlawful.

FORWARD-LOOKING STATEMENTS

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

  • Shire's proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement;
  • a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied;
  • ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma's business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; and
  • difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all;

and other risks and uncertainties detailed from time to time in Shire's or ViroPharma's filings with the U.S. Securities and Exchange Commission, including their respective most recent Annual Reports on Form 10-K.

For further information please contact:

Investor Relations

Eric Rojas
erojas@shire.com
+1-781-482-0999

Sarah Elton-Farr
seltonfarr@shire.com
+44-1256-894157

Media

Jessica Mann
jmann@shire.com
+44-1256-894-280

Gwen Fisher
gfisher@shire.com
+1-484-595-9836

 


'/>"/>
SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
2. MinuteClinic Opens First Clinic Locations in New Hampshire
3. Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
4. Shire to Present at the Bank of America Merrill Lynch Global Health Care Conference
5. Shire to Present at the Morgan Stanley Global Healthcare Conference
6. Shire Reports 7% Product Sales Growth: Anticipating Double Digit Non GAAP Earnings Growth in 2013
7. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
8. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
9. SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
10. Shire Acquires Premacure AB
11. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... , ... June 11, 2019 , ... ... Center and Grayken Center for Addiction will help combat the opioid epidemic by ... combines two pharmacy-specific educational interventions that have shown promise in reducing opioid-related harms, ...
(Date:6/11/2019)... ... June 11, 2019 , ... Intalere, ... today announced the latest enhanced release of OptiAnalytics Navigate. This best-in-class strategic ... customers. , “We are thrilled to offer these customer-focused new features ...
(Date:6/11/2019)... ... June 11, 2019 , ... MabPlex ... Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China ... the company's new Chief Executive Officer (CEO). Dr Chen will be responsible for ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... ... SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving ... being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose ...
(Date:6/12/2019)... ROCHELLE, Va. (PRWEB) , ... June 12, 2019 ... ... that Andrea Miller, a quality assurance expert with more than 25 years of ... and MDD Compliance for all classes of medical devices, has joined NDA Partners ...
(Date:6/12/2019)... ... June 12, 2019 , ... Ovation Travel Group, ... today announced that its Chairman and CEO Paul Metselaar has received the Children’s ... last Wednesday evening at New York City’s Capitale as part of the Children’s ...
(Date:6/12/2019)... ... June 12, 2019 , ... Millions of people across ... from participating in education or the workforce, and even from accessing health care. ... as a human right and address communication disability in ways that foster inclusion ...
(Date:6/11/2019)... ... 11, 2019 , ... The FSH Society today announced that ... regulators, biopharma companies, and academic thought leaders to discuss the current state of ... the world’s largest research-focused patient advocacy organization for FSHD, a hereditary muscle-damaging condition ...
Breaking Medicine News(10 mins):